The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort

J Affect Disord. 2022 Feb 15:299:335-343. doi: 10.1016/j.jad.2021.12.012. Epub 2021 Dec 11.

Abstract

Background: Pharmacological studies have yielded valuable insights into the role of the serotonin 4 receptor (HTR4) in major depressive episodes (MDE) and response to antidepressant drugs (AD). A genetic association has been shown between HTR4 and susceptibility to mood disorders. Our study aims at assessing the association between the HTR4 genetic polymorphism, rs1345697, and improvement in depressive symptoms and remission after antidepressant treatment in MDE patients.

Methods: 492 depressed patients from the METADAP cohort were treated prospectively for 6 months with ADs. The clinical outcomes according to HTR4 rs1345697 were compared after 1 (M1), 3 (M3), and 6 (M6) months of treatment. Mixed-effects logistic regression and adjusted linear models assessed the association between rs1345697 and 17-item Hamilton Depression Rating Scale (HDRS) score improvement and response/remission.

Results: Over the 6 months of treatment, mixed-effects regressions showed lower improvements in HDRS scores (Coefficient=1.52; Confident Interval (CI) 95% [0.37-2.67]; p = 0.009) and lower remission rates (Odds Ratio=2.0; CI95% [1.0-4.1]; p = 0.05) in GG homozygous patients as compared to allele A carriers.

Limitations: The major limitations of our study are the uncertainty of the rs1345697 effect on HTR4 function, the substantial drop-out rate, and the fact that analysis is not based on randomization between polymorphism groups.

Conclusions: In our study, patients who were homozygous carriers of the variant G of the HTR4 rs1345697 had lower depressive symptoms improvement and 2-fold lower remission rates after antidepressant treatment as compared to allele A carriers. Randomization study should be done to confirm these results.

Keywords: Antidepressant; HTR4 polymorphism; Major depressive episode; Pharmacogenetics; Remission.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antidepressive Agents / therapeutic use
  • Azo Compounds
  • Depressive Disorder, Major* / drug therapy
  • Depressive Disorder, Major* / genetics
  • Genotype
  • Humans
  • Polymorphism, Genetic
  • Receptors, Serotonin, 5-HT4* / therapeutic use
  • Treatment Outcome

Substances

  • Antidepressive Agents
  • Azo Compounds
  • 2-(4-methyl-2-thiazolylazo)-5-diethylaminophenol
  • Receptors, Serotonin, 5-HT4